Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011, Article ID 585919, 8 pages
http://dx.doi.org/10.1155/2011/585919
Review Article

HIV-Associated Tuberculosis

1CAPRISA Treatment Research Program, Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, 4013 Durban, South Africa
2Department of Public Health and Family Medicine, University of KwaZulu-Natal, 4013 Durban, South Africa
3Department of Epidemiology, Mailman School of Public Health at Columbia University, NY 10032, USA

Received 15 June 2010; Accepted 29 July 2010

Academic Editor: Katalin Andrea Wilkinson

Copyright © 2011 Kogieleum Naidoo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Zumla, P. Mwaba, J. Huggett, N. Kapata, D. Chanda, and J. Grange, “Reflections on the white plague,” The Lancet Infectious Diseases, vol. 9, no. 3, pp. 197–202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. WHO, “Global tuberculosis control—epidemiology, strategy, financing,” WHO Report, Geneva, Switzerland, 2009. View at Google Scholar
  3. UNAIDS, 2008 Report on the Global AIDS Epidemic, Geneva, Switzerland, 2008.
  4. J. Grange, M. Adhikari, Y. Ahmed et al., “Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa,” International Journal of Gynecology and Obstetrics, vol. 108, no. 3, pp. 181–183, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. Khan, T. Pillay, J. M. Moodley, and C. A. Connolly, “Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa,” AIDS, vol. 15, no. 14, pp. 1857–1863, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. M. R. Ramogale, J. Moodley, and M. H. Sebitloane, “HIV-associated maternal mortality—primary causes of death at King Edward VIII Hospital, Durban,” South African Medical Journal, vol. 97, no. 5, pp. 363–366, 2007. View at Google Scholar · View at Scopus
  7. E. Walters, M. F. Cotton, H. Rabie, H. S. Simon, L. O. Walters, and B. J. Marais, “Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy,” BMC Pediatrics, vol. 8, article no. 1, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. J. Bhat, V. K. Diwan, C. Chintu, M. Kabika, and J. Masona, “HIV, BCG and TB in children: a case control study in Lusaka, Zambia,” Journal of Tropical Pediatrics, vol. 39, no. 4, pp. 219–223, 1993. View at Google Scholar · View at Scopus
  9. H. J. Zar, M. F. Cotton, S. Strauss et al., “Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial,” British Medical Journal, vol. 334, no. 7585, pp. 136–139, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. H. McIlleron, G. Meintjes, W. J. Burman, and G. Maartens, “Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome,” Journal of Infectious Diseases, vol. 196, supplement 1, pp. S63–S75, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. B. Samb, P. S. Sow, S. Kony et al., “Risk factors for negative sputum acid-fast bacilli smears in pulmonary tuberculosis: results from Dakar, Senegal, a city with low HIV seroprevalence,” International Journal of Tuberculosis and Lung Disease, vol. 3, no. 4, pp. 330–336, 1999. View at Google Scholar · View at Scopus
  12. S. D. Greenberg, D. Frager, B. Suster, S. Walker, C. Stavropoulos, and A. Rothpearl, “Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance),” Radiology, vol. 193, no. 1, pp. 115–119, 1994. View at Google Scholar · View at Scopus
  13. T. Pepper, P. Joseph, C. Mwenya et al., “Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures,” International Journal of Tuberculosis and Lung Disease, vol. 12, no. 4, pp. 397–403, 2008. View at Google Scholar · View at Scopus
  14. D. C. Perlman, W. M. el-Sadr, E. T. Nelson et al., “Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG),” Clinical Infectious Diseases, vol. 25, no. 2, pp. 242–246, 1997. View at Google Scholar
  15. I. C. S. Bassett, B. Wang, and J. Giddy, “Intensive TB Screening for HIV-infected Patients Ready to Start ART in Durban, South Africa: Limitations of WHO Guidelines,” 2009, http://retroconference.org/2009/Abstracts/34392.htm.
  16. D. V. M. Edwards, N. Bangani, and R. Dawson, “Baseline Screening for TB among Patients Enrolling in an ART Service in South Africa,” 2009, http://www.retroconference.org/2009/abstracts/36271.htm.
  17. K. Dheda, K. Shean, A. Zumla et al., “Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study,” The Lancet, vol. 375, no. 9728, pp. 1798–1807, 2010. View at Google Scholar
  18. K. Dheda, V. Davids, L. Lenders et al., “Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples,” PLoS One, vol. 5, no. 3, article no. e9848, 2010. View at Google Scholar
  19. G. Roscigno, “Drug resistant TB and new diagnostics for people living with HIV: emerging results from FIND. IAS Conference; Catalysing HIV/TB research,” 2009, http://www.stoptb.org/wg/tb_hiv/assets/documents/DRUGRE~1.PDF.
  20. H. Albert, F. Bwanga, S. Mukkada et al., “Rapid screening of MDR-TB using molecular line probe assay is feasible in Uganda,” BMC Infectious Diseases, vol. 10, article no. 41, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. G. B. Migliori, A. Matteelli, D. Cirillo, and M. Pai, “Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current standards and challenges,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 19, no. 2, pp. 169–172, 2008. View at Google Scholar · View at Scopus
  22. D. Helb, M. Jones, E. Story et al., “Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology,” Journal of Clinical Microbiology, vol. 48, no. 1, pp. 229–237, 2010. View at Google Scholar
  23. D. A. J. Moore, C. A. W. Evans, R. H. Gilman et al., “Microscopic-observation drug-susceptibility assay for the diagnosis of TB,” New England Journal of Medicine, vol. 355, no. 15, pp. 1539–1550, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. H. Scaaf and A. Zumla, “Chapter 19: immune-based tests for tuberculosis,” in Tuberculosis: A comprehensive Clinical Reference, pp. 179–196, 2009. View at Google Scholar
  25. R. Mutetwa, C. Boehme, M. Dimairo et al., “Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients,” International Journal of Tuberculosis and Lung Disease, vol. 13, no. 10, pp. 1253–1259, 2009. View at Google Scholar · View at Scopus
  26. M. J. Reid and N. S. Shah, “Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings,” The Lancet Infectious Diseases, vol. 9, no. 3, pp. 173–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. A. Howard and W.M. El-Sadr, “Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned,” Clinical Infectious Diseases, vol. 50, supplement 3, pp. S238–S244, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. WHO, UNAIDS, Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities, Geneva, Switzerland, 2007.
  29. DOH, RSA, “Provinces launch their HIV Counselling and Testing (HCT) campaigns today,” 2010, http://www.info.gov.za/speeches/2010/10043011151001.htm.
  30. N. Padayatchi, “Unpublished data,” CAPRISA, UKZN, South Africa, 2010.
  31. WHO, “Interim policy on collaborative TB/HIV activities,” Stop TB Department and Department of HIV/AIDS, World Health Organization, Geneva, Switzerland, 2004.
  32. WHO, Global Tuberculosis Control: Surveillance, Planning, Financing, World Health Organisation, Geneva, Switzerland, 2008.
  33. S. S. Abdool Karim, K. Naidoo, A. Grobler et al., “Timing of initiation of antiretroviral drugs during tuberculosis therapy,” New England Journal of Medicine, vol. 362, no. 8, pp. 697–706, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. N. R. Gandhi, N. S. Shah, J. R. Andrews et al., “HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 1, pp. 80–86, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. C. D. Wells, J. P. Cegielski, L. J. Nelson et al., “HIV infection and multidrug-resistant tuberculosis—the perfect storm,” Journal of Infectious Diseases, vol. 196, supplement 1, pp. S86–S107, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. R. O'Donnell, N. Padayatchi, I. Master, G. Osburn, and C. R. Horsburgh, “Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa,” International Journal of Tuberculosis and Lung Disease, vol. 13, no. 7, pp. 855–861, 2009. View at Google Scholar · View at Scopus
  37. I. Eshun-Wilson, F. Havers, J. B. Nachega et al., “Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings,” Journal of the International Association of Physicians in AIDS, vol. 9, no. 2, pp. 104–108, 2010. View at Google Scholar
  38. M. A. French, P. Price, and S. F. Stone, “Immune restoration disease after antiretroviral therapy,” AIDS, vol. 18, no. 12, pp. 1615–1627, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. S. D. Lawn, L.-G. Bekker, and R. F. Miller, “Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals,” Lancet Infectious Diseases, vol. 5, no. 6, pp. 361–373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Meintjes, S. D. Lawn, F. Scano et al., “Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings,” The Lancet Infectious Diseases, vol. 8, no. 8, pp. 516–523, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. S. A. Shelburne III and R. J. Hamill, “The immune reconstitution inflammatroy syndrome,” AIDS Reviews, vol. 5, no. 2, pp. 67–79, 2003. View at Google Scholar · View at Scopus
  42. G. Breton, X. Duval, C. Estellat et al., “Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy,” Clinical Infectious Diseases, vol. 39, no. 11, pp. 1709–1712, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. D. J. Dhasmana, K. Dheda, P. Ravn, R. J. Wilkinson, and G. Meintjes, “Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management,” Drugs, vol. 68, no. 2, pp. 191–208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Kumarasamy, S. Chaguturu, K. H. Mayer et al., “Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India,” Journal of Acquired Immune Deficiency Syndromes, vol. 37, no. 5, pp. 1574–1576, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Narita, D. Ashkin, E. S. Hollender, and A. E. Pitchenik, “Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with aids,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 1, pp. 157–161, 1998. View at Google Scholar · View at Scopus
  46. R. A. M. Breen, C. J. Smith, I. Cropley, M. A. Johnson, and M. C. I. Lipman, “Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?” AIDS, vol. 19, no. 11, pp. 1201–1206, 2005. View at Google Scholar · View at Scopus
  47. J. Dautremer, J. Pacanowski, P.-M. Girard, V. Lalande, F. Sivignon, and J.-L. Meynard, “A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis,” AIDS, vol. 21, no. 3, pp. 381–382, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. L. John, J. Baalwa, P. Kalimugogo et al., “Response to ‘does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?’,” AIDS, vol. 19, no. 17, pp. 2049–2050, 2005. View at Google Scholar · View at Scopus
  49. S. M. Crowe, J. B. Carlin, K. I. Stewart, C. R. Lucas, and J. F. Hoy, “Predictive value of CD4 lymphocyte number for the development of opportunistic infections and malignancies in HIV-infected persons,” Journal of Acquired Immune Deficiency Syndromes, vol. 4, no. 8, pp. 770–776, 1991. View at Google Scholar · View at Scopus
  50. M. Muller, S. Wandel, R. Colebunders, S. Attia, H. Furrer, and M. Egger, “Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 10, no. 4, pp. 251–261, 2010. View at Google Scholar
  51. S. D. Lawn, L. Myer, L.-G. Bekker, and R. Wood, “Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa,” AIDS, vol. 21, no. 3, pp. 335–341, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. A. S. Walker, D. Ford, C. F. Gilks et al., “Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort,” The Lancet, vol. 375, no. 9722, pp. 1278–1286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Foster, P. Godfrey-Faussett, and J. Porter, “Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia,” AIDS, vol. 11, no. 7, pp. 919–925, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. J. E. Golub, P. Pronyk, L. Mohapi et al., “Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort,” AIDS, vol. 23, no. 5, pp. 631–636, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. E. Golub, V. Saraceni, S. C. Cavalcante et al., “The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil,” AIDS, vol. 21, no. 11, pp. 1441–1448, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. S. Woldehanna and J. Volmink, “Treatment of latent tuberculosis infection in HIV infected persons,” Cochrane Database of Systematic Reviews (Online), no. 1, article no. CD000171, 2004. View at Google Scholar · View at Scopus
  57. G. J. Churchyard, F. Scano, A. D. Grant, and R. E. Chaisson, “Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities,” Journal of Infectious Diseases, vol. 196, supplement 1, pp. S52–S62, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. S. B. Lucas, A. Hounnou, C. Peacock et al., “The mortality and pathology of HIV infection in a West African city,” AIDS, vol. 7, no. 12, pp. 1569–1579, 1993. View at Google Scholar · View at Scopus
  59. “IUATLD. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International union against tuberculosis committee on prophylaxis,” Bulletin of the World Health Organization, vol. 60, no. 4, pp. 555–564, 1982. View at Scopus
  60. A. M. F. De Pinho, G. Santoro-Lopes, L. H. Harrison, and M. Schechter, “Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil,” AIDS, vol. 15, no. 16, pp. 2129–2135, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Mosimaneotsile, A. Mathoma, B. Chengeta et al., “Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a botswana experience, 2004–2006,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 1, pp. 71–77, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. C. Akolo, I. Adetifa, S. Shepperd, and J. Volmink, “Treatment of latent tuberculosis infection in HIV infected persons (Review),” The Cochrane Collaboration, no. 1, article no. CD000171, 2010. View at Google Scholar
  63. N. Aït-Khaled, E. Alarcon, K. Bissell et al., “Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues,” International Journal of Tuberculosis and Lung Disease, vol. 13, no. 8, pp. 927–935, 2009. View at Google Scholar · View at Scopus
  64. “Preventive therapy against tuberculosis in people living with HIV,” Weekly Epidemiological Record, vol. 74, no. 46, pp. 385–398, 1999. View at Scopus
  65. A. Mwinga, M. Hosp, P. Godfrey-Faussett et al., “Twice weekly tuberculosis preventive therapy in HIV infection in Zambia,” AIDS, vol. 12, no. 18, pp. 2447–2457, 1998. View at Google Scholar · View at Scopus
  66. WHO, “Guidance for national TB programmes (NTPs) on managing TB in children,” Geneva, Switzerland, 2006, http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf.
  67. WHO, UNAIDS, “Policy statement on preventive therapy against tuberculosis in people living with HIV Report of a meeting held in Geneva,” Geneva, Switzerland, 1998.
  68. E. L. Korenromp, F. Scano, B. G. Williams, C. Dye, and P. Nunn, “Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review,” Clinical Infectious Diseases, vol. 37, no. 1, pp. 101–112, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. D. Maher, A. Harries, and H. Getahun, “Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies,” Tropical Medicine and International Health, vol. 10, no. 8, pp. 734–742, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. K. F. Mallory, G. J. Churchyard, I. Kleinschmidt, K. M. De Cock, and E. L. Corbett, “The impact of HIV infection on recurrence of tuberculosis in South African gold miners,” International Journal of Tuberculosis and Lung Disease, vol. 4, no. 5, pp. 455–462, 2000. View at Google Scholar · View at Scopus
  71. P. C. Onyebujoh, I. Ribeiro, and C. C. Whalen, “Treatment options for HIV-associated tuberculosis,” Journal of Infectious Diseases, vol. 196, supplement 1, pp. S35–S45, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. P. Sonnenberg, J. Murray, J. R. Glynn, S. Shearer, B. Kambashi, and P. Godfrey-Faussett, “HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers,” Lancet, vol. 358, no. 9294, pp. 1687–1693, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. D. W. Fitzgerald, M. Desvarieux, P. Severe, P. Joseph, W. D. Johnson Jr., and J. W. Pape, “Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial,” Lancet, vol. 356, no. 9240, pp. 1470–1474, 2000. View at Google Scholar · View at Scopus
  74. J. H. Perriens, M. E. St. Louis, Y. B. Mukadi et al., “Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months,” New England Journal of Medicine, vol. 332, no. 12, pp. 779–784, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. D. L. Hanson, S. Y. Chu, K. M. Farizo et al., “Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses,” Archives of Internal Medicine, vol. 155, no. 14, pp. 1537–1542, 1995. View at Google Scholar
  76. O. Kirk, A. Mocroft, C. Pedersen et al., “Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 3, pp. 865–872, 2000. View at Google Scholar · View at Scopus
  77. S. D. Lawn, L.-G. Bekker, and R. Wood, “How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control,” AIDS, vol. 19, no. 11, pp. 1113–1124, 2005. View at Google Scholar · View at Scopus
  78. WHO, “WHO policy on TB infection control in health-care facilities, congregate settings and households,” Geneva, Switzerland, 2009.
  79. N. N. Bock, P. A. Jensen, B. Miller, and E. Nardell, “Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment,” Journal of Infectious Diseases, vol. 196, supplement 1, pp. S108–S113, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. A. R. Escombe, D. A. J. Moore, R. H. Gilman et al., “Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmissio,” PLoS Medicine, vol. 6, no. 3, article no. e43, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. A. R. Escombe, C. C. Oeser, R. H. Gilman et al., “Natural ventilation for the prevention of airborne contagion,” PLoS Medicine, vol. 4, no. 2, article no. e68, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. M. W. First, R. A. Weker, S. Yasui, and E. A. Nardell, “Monitoring human exposures to upper-room germicidal ultraviolet irradiation,” Journal of Occupational and Environmental Hygiene, vol. 2, no. 5, pp. 285–292, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. J. Francis, “Curry National Tuberculosis Center. Tuberculosis infection control: A practical manual for preventing TB,” 2007, http://www.nationaltbcenter.edu/TB_IC/docs/06SputumInduction.pdf.
  84. H. Humphreys, “Control and prevention of healthcare-associated tuberculosis: the role of respiratory isolation and personal respiratory protection,” Journal of Hospital Infection, vol. 66, no. 1, pp. 1–5, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. B. Gamage, D. Moore, R. Copes, A. Yassi, and E. Bryce, “Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literature,” American Journal of Infection Control, vol. 33, no. 2, pp. 88–96, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. D. Moore, B. Gamage, E. Bryce, R. Copes, and A. Yassi, “Protecting health care workers from SARS and other respiratory pathogens: organizational and individual factors that affect adherence to infection control guidelines,” American Journal of Infection Control, vol. 33, no. 2, pp. 114–121, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus